Last reviewed · How we verify
Lidocaine topical system 1.8%
At a glance
| Generic name | Lidocaine topical system 1.8% |
|---|---|
| Also known as | ZTlido, Lidocaine patch 1.8%, lidocaine patch 1.8% |
| Sponsor | Scilex Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% Under Conditions of Heat and Exercise (PHASE1)
- Pharmacokinetic Study of Lidocaine Patch 1.8% Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects (PHASE1)
- Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Generic Lidocaine Patch 5% in Healthy, Adult, Human Subjects (PHASE1)
- Pain and Anxiety Levels of Sleeperone Electronic Anesthesia System in Pediatric Patients (NA)
- Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin. (NA)
- Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches (PHASE1)
- Pharmacokinetic Study of SP-103 in Healthy Adult Human Subjects (PHASE1)
- Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% With Water Exposure (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidocaine topical system 1.8% CI brief — competitive landscape report
- Lidocaine topical system 1.8% updates RSS · CI watch RSS
- Scilex Pharmaceuticals, Inc. portfolio CI